| 000 | 01886 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515002805.0 | ||
| 264 | 0 | _c20060127 | |
| 008 | 200601s 0 0 eng d | ||
| 022 | _a0925-5710 | ||
| 024 | 7 |
_a10.1532/IJH97.05044 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShigeno, Kazuyuki | |
| 245 | 0 | 0 |
_aArsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. _h[electronic resource] |
| 260 |
_bInternational journal of hematology _cOct 2005 |
||
| 300 |
_a224-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArsenic Trioxide |
| 650 | 0 | 4 |
_aArsenicals _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Marrow _xpathology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aJapan |
| 650 | 0 | 4 |
_aLeukemia, Promyelocytic, Acute _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xbiosynthesis |
| 650 | 0 | 4 |
_aOncogene Proteins, Fusion _xbiosynthesis |
| 650 | 0 | 4 |
_aOxides _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aNaito, Kensuke | |
| 700 | 1 | _aSahara, Naohi | |
| 700 | 1 | _aKobayashi, Miki | |
| 700 | 1 | _aNakamura, Satoki | |
| 700 | 1 | _aFujisawa, Sinya | |
| 700 | 1 | _aShinjo, Kaori | |
| 700 | 1 | _aTakeshita, Akihiro | |
| 700 | 1 | _aOhno, Ryuzo | |
| 700 | 1 | _aOhnishi, Kazunori | |
| 773 | 0 |
_tInternational journal of hematology _gvol. 82 _gno. 3 _gp. 224-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1532/IJH97.05044 _zAvailable from publisher's website |
| 999 |
_c15837279 _d15837279 |
||